Catalent increases controlled release development capabilities
Expansion will allow products to move through the development stages to commercialisation within the same site
Catalent Pharma Solutions is undertaking a major expansion of its development capabilities for oral controlled release dosage forms. The move will enable the company to offer formulation development and optimisation services in its facility in Winchester, Kentucky, and complements that site’s existing pilot scale and commercial capabilities for controlled release tablets and capsules.
The addition of formulation development and optimisation services in Winchester will allow products to move through the development stages to commercialisation within the same site; reducing the need for additional technology transfers and facilitating a faster time to market.
This expansion also builds upon Catalent’s existing controlled release development capabilities in Somerset, New Jersey and Schorndorf, Germany.
‘This latest investment in our modified release group continues our long established heritage in this field and offers our customers a more comprehensive service at our Winchester facility and across our network,’ said Ian Muir, president of Catalent’s Modified Release Technology business.
The new formulation and process development area is expected to be open for business in early December. A major expansion of development and commercial capabilities in Catalent’s oral controlled release facility in Schorndorf, Germany, is also underway for a planned launch in 2012 and will allow global and European customers to take advantage of Catalent’s expertise in solving the most complex formulation and scale-up challenges.
